Compare BioNTech SE - ADR (BNTX) vs EOG Resources Inc (EOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs EOG Resources Inc — how do they compare? BioNTech SE - ADR trades at $93.1 (market cap $23.31B), while EOG Resources Inc trades at $142.18 (market cap $75.22B). The key difference: EOG Resources Inc is far larger — about 3.2× BioNTech SE - ADR's market cap, and EOG Resources Inc pays a 2.85% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | EOG | |
|---|---|---|
Market Cap | $23.31B | $75.22B |
Sector | Health | Energy |
52-Week High | $119.34 | $149.89 |
52-Week Low | $83.89 | $101.78 |
Enterprise Value | $6.60B | $78.56B |
Dividend Yield | — | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
EOG Resources trades at $142.22, up 5.55% today, with strong earnings beats in recent quarters and a bullish technical signal. The stock shows robust profitability with a 25.81% net income margin and attractive valuation metrics, including a P/E of 11.16. Recent news highlights operational strength and institutional buying interest, supporting positive momentum.
The outlook remains favorable with a consensus price target of $157.88, indicating potential upside. Key risks include oil price volatility and capital expenditure intensity, but disciplined cost controls and shareholder returns provide stability. The stock presents a compelling opportunity for growth-oriented investors seeking energy exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →
